Growth Hormone Secretagogues Show Diverse Effects Across Multiple Organ Systems
Background
Growth hormone secretagogues (GHS) are a novel class of compounds designed to stimulate the release of growth hormone (GH). Previous research has shown their potential in various applications, including cardioprotection in rats and increasing growth velocity in children with short stature or GH deficiency. In adults, GHS have been observed to increase GH and insulin-like growth factor-I (IGF-I) levels, reverse diet-induced catabolism, and improve body composition in obese individuals; however, the direct effects of GHS on organ systems and their long-term efficacy remain largely unknown.
Results
The review highlighted several key findings regarding GHS effects. In animal studies, the GHS hexarelin demonstrated significant cardioprotective effects in rats. For pediatric populations, GHS were shown to increase growth velocity in children diagnosed with short stature or growth hormone deficiency. In adults, a combined infusion of GH releasing peptide-2 (GHRP-2) and thyrotropin releasing hormone (TRH) was found to elevate circulating concentrations of both GH and insulin-like growth factor-I (IGF-I). Oral GHS administration in healthy volunteers successfully reversed diet-induced catabolism, and notably, in healthy obese men, oral GHS treatment led to an increase in fat-free mass, indicating a positive impact on body composition.
Why It Matters
This comprehensive review underscores the broad therapeutic potential of GHS across multiple organ systems and conditions. The observed benefits, from cardioprotection and growth promotion to metabolic improvements and body composition changes, suggest GHS could address significant unmet medical needs. Further research into the direct mechanisms and long-term safety and efficacy of GHS is crucial to fully evaluate their potential for clinical use in conditions like GH deficiency, sarcopenia, and metabolic disorders. Future steps should involve conducting Phase II and Phase III human trials with extended durations to establish definitive clinical utility.